Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials

Table 3 Clinical cure at TOC visit by high-risk factor and pathogen type (CE population)

	Number of patients (ceftobiprole/ comparator)	Clinical cure at TOC (%, ceftobiprole/ comparator)	Treatment difference (%)^a	95% CI^b
All patients (CAP)	231/238	86.6/87.4	−0.8	−6.9, 5.3
High-risk patients (CAP)	193/205	86.0/86.8	−0.8	−7.6, 5.9
Any Gram-positive	29/40	89.7/90.0	−0.3	−14.8, 14.1
Any Gram-negative	34/33	82.4/90.9	−8.6	−24.7, 7.6
Any S. pneumoniae	26/33	92.3/90.9	1.4	−12.8, 15.6
PORT ≥ III	126/117	86.5/86.3	0.2	−8.4, 8.8
PORT ≥ IV	51/58	90.2/84.5	5.7	−6.7, 18.1
Sepsis	123/135	84.6/86.7	−2.1	−10.7, 6.5
Age ≥ 75 years	39/50	92.3/86.0	6.3	−6.4, 19.1
COPD	51/59	86.3/86.4	−0.2	−13.0, 12.7
ICU	25/26	72.0/61.5	10.5	−15.2, 36.1
All patients (HAP, excl. VAP)	198/185	77.8/76.2	1.6	−6.9, 10.0
High-risk patients (HAP, excl. VAP)	169/138	75.7/71.7	4.0	−5.9, 13.9
Any Gram-positive	52/53	69.2/69.8	−2.5	−19.9, 15.0
Any Gram-negative	65/60	67.7/73.3	−5.6	−21.6, 10.3
Mixed/polymicrobial	29/35	62.1/68.6	−6.5	−29.9, 16.9
Any S. aureus	35/38	68.6/71.1	−2.5	− 23.6, 18.6
APACHE score ≥ 15	67/59	68.7/64.4	4.2	−12.3, 20.8
>10 comorbidities	63/61	73.0/67.2	5.8	−10.3, 21.9
Mechanical ventilation	38/37	55.3/40.5	14.7	−7.6, 37.1
Age ≥ 75 years	59/54	72.9/77.8	−4.9	−20.8, 11.0
COPD	55/39	83.6/76.9	6.7	−9.7, 23.2
ICU	73/59	69.9/66.1	3.8	−12.3, 19.8

^aBetween treatment difference calculated as ceftobiprole minus ceftriaxone ± linezolid for patients with CAP, and ceftobiprole minus ceftazidime plus linezolid for patients with HAP (excluding VAP)
^bTwo-sided 95% CI is based on a normal approximation to the difference of the two proportions
APACHE Acute Physiology and Chronic Health Evaluation, CAP community-acquired pneumonia, CE clinically evaluable, CI confidence interval, COPD chronic obstructive pulmonary disease, HAP hospital-acquired pneumonia, ICU intensive care unit, MRSA methicillin-resistant Staphylococcus aureus, PORT Patient Outcome Research Team, TOC test-of-cure, VAP, ventilator-associated pneumonia

ISSN: 1471-2334